InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals” or the “Company”) has on May 20th entered into a conditional agreement to acquire all shares in Flerie Invest AB.

InDex Pharmaceuticals and Flerie invite to a digital investor meeting in order to inform shareholders about the Transaction and to provide shareholders and stakeholders with the opportunity to ask questions. The meeting will be held by Jenny Sundqvist, CEO, and Johan Giléus, CFO and deputy CEO of InDex Pharmaceuticals, together with Ted Fjällman, CEO of Flerie and intended CEO of New Flerie after completion of the Transaction.